Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children after Symptomatic Primary and Postprimary DENV Infection

Journal of Infectious Diseases

Volumn 213, Issue 9, 2016, Pages 1428-1435

  Clapham, Hannah E ^a   Rodriguez Barraquer, Isabel ^a   Azman, Andrew S ^a   Althouse, Benjamin M ^b,c,d   Salje, Henrik ^a   Gibbons, Robert V ^e   Rothman, Alan L ^f   Jarman, Richard G ⁱ   Nisalak, Ananda ⁱ   Thaisomboonsuk, Butsaya ⁱ   Kalayanarooj, Siripen ^j   Nimmannitya, Suchitra ^j   Vaughn, David W ⁱ   Green, Sharone ^h   Yoon, In Kyu ^k   Cummings, Derek A T ^a,g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b INSTITUTE FOR DISEASE MODELING   (United States)

^c SANTA FE INSTITUTE   (Mexico)

^d NEW MEXICO STATE UNIVERSITY   (United States)

^e US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^f UNIVERSITY OF RHODE ISLAND   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ Armed Forces Research Institute of Medical Sciences San Francisco   (United States)

^j QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^k International Vaccine Institute   (South Korea)

more..

Author keywords

dengue; longitudinal antibody kinetics; neutralizing antibody; vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHILD; CONVALESCENCE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; THAILAND; VIRUS TRANSMISSION; BLOOD; DENGUE VIRUS; IMMUNOLOGY; KINETICS; LONGITUDINAL STUDY; PRESCHOOL CHILD;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; HUMANS; KINETICS; LONGITUDINAL STUDIES; THAILAND;

EID: 84971614213     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv759     Document Type: Article

References (24)

1. Bhatt S, Gething PW, Brady OJ, et al. the global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Nisalak A, Endy TP, Nimmannitya S, et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 2003; 68:191-202.
3. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
4. Snow GE, Haaland B, Ooi EE, Gubler DJ. Research on dengue during world war II revisited. Am J Trop Med Hyg 2014; 91:1203-17.
5. Anderson KB, Gibbons RV, Cummings DAT, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014; 209:360-8.
6. Reich NG, Shrestha S, King AA, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 2013; 10:20130414.
7. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7:e2357.
8. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science (80-) 2010; 328:745-8.
9. Olkowski S, Forshey BM, Morrison AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013; 208:1026-33.
10. Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007; 77:910-3.
11. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313-21.
12. Innis BL, Nisalak A, Nimmannitya S, et al. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40:418-27.
13. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322-30.
14. Libraty DH, Endy TP, Houng H-SH, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-21.
15. Salje H, Rodríguez-Barraquer I, Rainwater-Lovett K, et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis 2014; 8:8-10.
16. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90.
17. Team R. R development core team. R A Lang Environ Stat Comput 2013; 55:275-86.
18. Vaughn DW. Invited commentary: dengue lessons from Cuba. Am J Epidemiol 2000; 152:800-3.
19. Endy TP, Yoon I-K, Mammen MP. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol 2010; 338:1-13.
20. Guzman MG, Alvarez M, Rodriguez-Roche R, et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007; 13:282-6.
21. Buddhari D, Aldstadt J, Endy TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis 2014; 8:e3230.
22. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
23. Rodríguez-Barraquer I, Buathong R, Iamsirithaworn S, et al. Revisiting rayong: shifting seroprofiles of dengue in thailand and their implications for transmission and control. Am J Epidemiol 2014; 179:353-60.
24. de Alwis R, Beltramello M, Messer WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011; 5:1-8.